Nyrada Inc. (ASX:NYR)

Market Cap	69.25M
Revenue (ttm)	2.40M
Net Income (ttm)	-4.85M
Shares Out	238.81M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	445,172
Average Volume	355,327
Open	0.2700
Previous Close	0.2700
Day's Range	0.2700 - 0.2900
52-Week Range	0.0510 - 0.3700
Beta	0.67
RSI	55.92
Earnings Date	Aug 22, 2025

About Nyrada

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: United States
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NYR

Financial Performance

In 2025, Nyrada's revenue was 2.40 million, a decrease of -26.07% compared to the previous year's 3.24 million. Losses were -4.85 million, 248.3% more than in 2024.